[go: up one dir, main page]

NO20075074L - Kinazolinon T-type-kalsiumkanalantagonister - Google Patents

Kinazolinon T-type-kalsiumkanalantagonister

Info

Publication number
NO20075074L
NO20075074L NO20075074A NO20075074A NO20075074L NO 20075074 L NO20075074 L NO 20075074L NO 20075074 A NO20075074 A NO 20075074A NO 20075074 A NO20075074 A NO 20075074A NO 20075074 L NO20075074 L NO 20075074L
Authority
NO
Norway
Prior art keywords
type calcium
kinazolinone
calcium channel
channel antagonists
compounds
Prior art date
Application number
NO20075074A
Other languages
English (en)
Inventor
James C Barrow
Rowena V Cube
Phung Le Ngo
Kenneth E Rittle
Zhiqiang Yang
Steven D Young
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Publication of NO20075074L publication Critical patent/NO20075074L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/78—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
    • C07D239/80—Oxygen atoms
    • C07D239/82—Oxygen atoms with an aryl radical attached in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/78—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
    • C07D239/80—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Anesthesiology (AREA)
  • Addiction (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Den foreliggende oppfinnelse vedrører kinazolinonforbindelser som er antagonister av T-type-kalsiumkanaler, og som er anvendelige ved behandling eller forebygging av forstyrrelser og sykdommer hvori T-type-kalsiumkanaler er involvert. Oppfinnelsen vedrører også farmasøytiske blandinger inneholdende disse forbindelser og anvendelse av disse forbindelser og blandinger ved forebygging eller behandling av slike sykdommer hvori T-type-kalsiumkanaler er involvert.
NO20075074A 2005-03-09 2007-10-08 Kinazolinon T-type-kalsiumkanalantagonister NO20075074L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US65995405P 2005-03-09 2005-03-09
PCT/US2006/008177 WO2006098969A2 (en) 2005-03-09 2006-03-08 Quinazolinone t-type calcium channel antagonists

Publications (1)

Publication Number Publication Date
NO20075074L true NO20075074L (no) 2007-11-30

Family

ID=36992208

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20075074A NO20075074L (no) 2005-03-09 2007-10-08 Kinazolinon T-type-kalsiumkanalantagonister

Country Status (15)

Country Link
US (2) US7745452B2 (no)
EP (1) EP1858520B1 (no)
JP (1) JP2008533020A (no)
KR (1) KR20070110081A (no)
CN (1) CN101137380A (no)
AT (1) ATE527243T1 (no)
AU (1) AU2006223469A1 (no)
BR (1) BRPI0608343A2 (no)
CA (1) CA2600868A1 (no)
IL (1) IL185391A0 (no)
MX (1) MX2007010965A (no)
NO (1) NO20075074L (no)
RU (1) RU2007137266A (no)
WO (1) WO2006098969A2 (no)
ZA (1) ZA200706740B (no)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE527243T1 (de) * 2005-03-09 2011-10-15 Merck Sharp & Dohme Calciumkanal-antagonisten vom typ chinazolinon t
CA2685753A1 (en) 2007-05-09 2008-11-20 Neuromed Pharmaceuticals Ltd. Bicyclic pyrimidine derivatives as calcium channel blockers
WO2009009015A1 (en) * 2007-07-10 2009-01-15 Merck & Co., Inc. Quinazolinone t-type calcium channel antagonists
US8273749B2 (en) 2007-10-04 2012-09-25 Merck Sharp & Dohme Corp. N-substituted oxindoline derivatives as calcium channel blockers
WO2009044788A1 (ja) * 2007-10-05 2009-04-09 Banyu Pharmaceutical Co., Ltd. ベンゾオキサジノン誘導体
JP5718233B2 (ja) * 2008-10-20 2015-05-13 ザ ガバメント オブ ザ ユナイテッド ステイツ オブ アメリカ アズ リプレゼンテッド バイ ザ セクレタリー オブ ザ デパートメント オブ ヘルス アンド ヒューマン サービシーズ 甲状腺刺激ホルモン受容体（ｔｓｈｒ）の低分子量アゴニスト
FR2937552B1 (fr) * 2008-10-27 2011-05-06 Biocodex Composition pharmaceutique destinee a la prevention ou au traitement du syndrome de sevrage alcoolique
WO2011127388A2 (en) 2010-04-08 2011-10-13 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Inverse agonists and neutral antagonists for the tsh receptor
CN102906074A (zh) * 2010-05-24 2013-01-30 东亚荣养株式会社 稠合咪唑衍生物
RU2650107C2 (ru) * 2012-09-26 2018-04-09 Мерк Патент Гмбх Производные хиназолинона в качестве ингибиторов parp
IN2014CH00304A (no) * 2014-01-24 2015-09-04 Discovery Intermediates Pvt Ltd
US9145388B2 (en) 2014-02-19 2015-09-29 King Fahd University Of Petroleum And Minerals 6-piperazinyl-3,4-dihydroquinazolin-2(1H)-ones
CN106459030B (zh) 2014-05-28 2019-01-29 东亚荣养株式会社 取代托品烷衍生物
FI3364993T3 (fi) 2015-10-22 2023-01-13 Menetelmiä angelmanin oireyhtymän hoitamiseksi
CA3053781A1 (en) 2017-02-15 2018-08-23 Cavion, Inc. Benzopyran and naphalene derivatives and their uses as calium channel inhibitors
CN106749045B (zh) * 2017-03-03 2020-02-14 上海交通大学 一种d-氨基酸氧化酶抑制剂及其制法和应用
CA3061720A1 (en) 2017-04-26 2018-11-01 Cavion, Inc. Methods for improving memory and cognition and for treating memory and cognitive disorders
JP7480131B2 (ja) 2018-10-03 2024-05-09 カビオン・インコーポレイテッド （ｒ）－２－（４－イソプロピルフェニル）－ｎ－（１－（５－（２，２，２－トリフルオロエトキシ）ピリジン－２－イル）エチル）アセトアミドを使用した本態性振戦の処置
CN114340670A (zh) 2019-07-11 2022-04-12 普拉克西斯精密药物股份有限公司 T-型钙通道调节剂的制剂及其使用方法
KR20240089791A (ko) 2021-10-20 2024-06-20 인실리코 메디신 아이피 리미티드 메티오닌 아데노실트랜스퍼라제 2a (mat2a) 억제제 및 그의 용도

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL102764A0 (en) * 1991-08-16 1993-01-31 Merck & Co Inc Quinazoline derivatives,and pharmaceutical compositions containing them
AU2436792A (en) * 1991-08-16 1993-03-16 Merck & Co., Inc. Quinazoline derivatives as inhibitors of hiv reverse transcriptase
DE4320347A1 (de) 1993-06-19 1994-12-22 Boehringer Mannheim Gmbh Quinazolin-Derivate und diese enthaltende Arzneimittel
WO1999044612A1 (en) * 1998-03-02 1999-09-10 Cocensys, Inc. Substituted quinazolines and analogs and the use thereof
GB0008269D0 (en) * 2000-04-05 2000-05-24 Astrazeneca Ab Combination chemotherapy
JP3691341B2 (ja) * 2000-05-16 2005-09-07 日新製鋼株式会社 精密打抜き性に優れたオーステナイト系ステンレス鋼板
WO2004035000A2 (en) * 2002-10-17 2004-04-29 Merck & Co., Inc. Enhancement of sleep with t-type calcium channel antagonists
JP4719681B2 (ja) * 2003-09-23 2011-07-06 メルク・シャープ・エンド・ドーム・コーポレイション キナゾリンカリウムチャネル阻害剤
US20070010537A1 (en) * 2004-08-20 2007-01-11 Kazumasa Hamamura Fused pyramidine derivative and use thereof
ATE527243T1 (de) * 2005-03-09 2011-10-15 Merck Sharp & Dohme Calciumkanal-antagonisten vom typ chinazolinon t
US20070162299A1 (en) * 2006-01-12 2007-07-12 Atsuko Ito Materials location system and selecting method of materials receiving locations

Also Published As

Publication number Publication date
BRPI0608343A2 (pt) 2016-10-04
EP1858520A2 (en) 2007-11-28
EP1858520B1 (en) 2011-10-05
IL185391A0 (en) 2008-02-09
ZA200706740B (en) 2008-09-25
WO2006098969A2 (en) 2006-09-21
KR20070110081A (ko) 2007-11-15
MX2007010965A (es) 2007-09-19
WO2006098969A3 (en) 2007-03-01
US7745452B2 (en) 2010-06-29
ATE527243T1 (de) 2011-10-15
AU2006223469A1 (en) 2006-09-21
JP2008533020A (ja) 2008-08-21
US20080167329A1 (en) 2008-07-10
EP1858520A4 (en) 2010-02-10
CA2600868A1 (en) 2006-09-21
CN101137380A (zh) 2008-03-05
US20100261741A1 (en) 2010-10-14
RU2007137266A (ru) 2009-04-20

Similar Documents

Publication Publication Date Title
NO20075074L (no) Kinazolinon T-type-kalsiumkanalantagonister
MX2010004530A (es) Antagonistas de los canales de calcio tipo t de heterociclo fenil amida.
WO2007120729A3 (en) Pyridyl amide t-type calcium channel antagonists
TW200714604A (en) Substituted heterocycles and the uses thereof
DE602007008434D1 (de) Rezeptoren
EA201690265A2 (ru) Фармацевтические композиции, содержащие замещенные ациланилиды
WO2007002884A3 (en) 4-fluoro-piperidine t-type calcium channel antagonists
DE602004013563D1 (de) Rantagonisten
EP1606286A4 (en) BENZODIAZEPINE SPIROHYDANTOINES AS CGRP RECEPTOR ANTAGONISTS
EA200901166A1 (ru) Соединения и композиции в качестве модуляторов активности gpr 119
TW200716546A (en) Oxindole compounds and their uses as therapeutic agents
CY1110965T1 (el) Επιπροσθετες ετεροπολυκυκλικες ενωσεις και η χρηση τους ως ανταγωνιστες μεταβολοτροπικου υποδοχεα γλουταμικου
EA200901032A1 (ru) Соединения и композиции в качестве модуляторов активности gpr119
WO2008008551A3 (en) 2-substituted proline bis-amide orexin receptor antagonists
EA201170531A1 (ru) Соединения на основе пиридина и пиримидина в качестве ингибиторов сигнального пути wnt для лечения рака
TW200738724A (en) Substituted 4-amino-pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis
ATE516803T1 (de) Aryl-spirohydantoin-cgrp-rezeptor-antagonisten
MA31451B1 (fr) Antagonistes des recepteurs de l'orexine de pyridyl piperidine.
MX2009006704A (es) Derivados de amina triciclicos como inhibidores de proteina de tirosina cinasa.
MX2009010127A (es) Compuestos utiles como inhibidores de janus cinasas.
MY145077A (en) Pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis
ATE493412T1 (de) Spirohydantoin-aryl-cgrp-rezeptorantagonisten
TW200724543A (en) Heterocyclic compounds and their uses as therapeutic agents
DE602004020070D1 (de) Thienopyrimidin-derivate als kaliumkanal-inhibitoren
WO2007002361A3 (en) 3-fluoro-piperidine t-type calcium channel antagonists

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application